Thyroid Nodules: Is Microwave Ablation the Future?
"A new study compares microwave ablation (MWA) to radiofrequency ablation (RFA) for treating benign thyroid nodules, revealing key differences that could change how we approach thyroid health."
Thyroid nodules are common, and while most are benign, they can cause discomfort or cosmetic concerns, leading many to seek minimally invasive treatments. Radiofrequency ablation (RFA) has been a popular choice, but newer methods like microwave ablation (MWA) are emerging as promising alternatives.
A recent study published in the International Journal of Hyperthermia dives into a detailed comparison between MWA and bipolar RFA, focusing on how they differ in energy transmission, application duration, and the number of shots required. The goal? To see if MWA offers any tangible advantages over RFA in treating benign thyroid nodules.
This article breaks down the study's findings, explaining the key differences between these two ablation techniques and what they mean for people seeking effective and less invasive options for managing thyroid nodules. Whether you're exploring treatment options or simply curious about the latest advancements in thyroid health, this information will provide a clearer picture of what MWA can offer.
Long-Term Outcomes and Treatment Trends
Thermal ablation is widely accepted as an effective and safe alternative to surgery for benign thyroid nodules, though long-term studies have reported nodule regrowth and recurring symptoms. A study of radiofrequency ablation (RFA) referrals found that referral numbers increased over time, while the proportion of patients treated decreased yearly, primarily because physicians more often deferred treatment. A separate long-term review searched for studies published through August 25, 2019, that reported follow-up longer than three years. ClinicalTrials.gov also lists a study of ultrasound-guided RFA involving benign and indeterminate nodules, low-risk differentiated thyroid cancer, and recurrent papillary thyroid cancer.
Surgery and Image-Guided Alternatives
Thyroidectomy remains the gold-standard treatment for benign symptomatic or enlarging nodules, malignant nodules, and metastatic lymph node disease. Image-guided interventions have emerged as alternatives, and percutaneous ethanol ablation is an accepted first-line treatment for recurring cystic nodules. Thermal and chemical ablation are minimally invasive compared with surgery, but complications and morbidity can occur if procedures are performed incorrectly or by inexperienced practitioners. For nodules with a significant cystic component, guidelines describe ethanol ablation as an adjunct to thermal ablation; consistent use of the trans-isthmic approach and moving-shot technique can help reduce thermal injury to nearby critical structures and skin.
MWA vs. RFA: Key Differences in Treating Thyroid Nodules
The study, led by Christian Vorländer and colleagues, involved 60 patients with 65 thyroid nodules, comparing microwave ablation (MWA) to radiofrequency ablation (RFA). Researchers meticulously analyzed procedural characteristics, including treatment time, the number of energy bursts (shots), and total energy delivered, alongside clinical outcomes like complication rates and nodule volume reduction after three months.
- Energy Transmission: Both MWA and RFA delivered comparable amounts of energy to the thyroid nodules. The energy transmitted per milliliter of nodule tissue was also similar between the two methods.
- Procedure Time & Power: No significant differences were found in the overall duration of the ablation procedure or the power used during treatment.
- Number of Shots: MWA required significantly fewer 'shots' or applications compared to RFA to treat the entire nodule. This could translate to reduced discomfort and potentially shorter procedure times.
- Volume Reduction: Both MWA and RFA led to a significant reduction in nodule volume after three months, with no statistical difference between the two.
- Complications: Both treatments were generally well-tolerated. One patient in the MWA group experienced a transient Horner's syndrome, which resolved without further intervention. No major complications like nodule rupture or nerve injuries were reported.
Evidence Across Ablation Research
A bibliometric analysis examined publications on ultrasound-guided thermal ablation for thyroid nodules indexed in the Web of Science Core Collection through October 1, 2022. A systematic review and meta-analysis comparing radiofrequency ablation (RFA) with microwave ablation (MWA) noted that three included studies used retrospective cohort designs, which did not allow participant randomization. A 2025 scoping review reported varied incidence rates for Horner syndrome: 0.4%–4.2% with MWA, 0.1%–1.5% with RFA, and 1.5%–6.7% with high-intensity focused ultrasound; incidence for percutaneous ethanol injection was unspecified because of insufficient data. A 2026 review describes ultrasound-guided thermal ablation as a minimally invasive treatment option for benign nodules and selected low-risk thyroid cancers.
Comparing Ablation Options
A study published January 16, 2026, evaluated a non-cooled microwave ablation system against a radiofrequency ablation system for benign thyroid nodules. It included 56 patients treated between October 2022 and July 2023; the available source excerpt does not provide comparative outcome figures. A 2024 network meta-analysis set out to compare the efficacy and safety of RFA, MWA, ethanol ablation, and laser ablation using randomized controlled trials identified across four databases. The supplied excerpts describe these study designs and aims but do not establish which treatment is more effective or safer.
The Future of Thyroid Nodule Treatment
This study adds to the growing body of evidence supporting the use of minimally invasive techniques like MWA and RFA for managing benign thyroid nodules. The fact that MWA can achieve comparable results to RFA with fewer applications makes it an attractive option for both patients and clinicians.
Consensus and Individualized Care
An international consensus on thermal ablation for benign thyroid nodules was developed by a multidisciplinary panel of 30 experts with relevant experience. The panel reviewed, rated, and revised recommendations through multiple rounds of the modified Delphi method. Research on thermal ablation for benign non-functioning nodules in multinodular goiter emphasizes monitoring and treating each nodule individually. A separate systematic review was designed to assess whether RFA for benign non-functioning nodules is cost-effective compared with surgery, but the supplied source excerpt does not report its findings.
Market Forecasts and Technology Trends
A market report published in December 2025 projects the thyroid ablation devices market will grow from USD 186.4 million in 2024 to USD 495.8 million by 2035, a forecast compound annual growth rate of 9.3% for 2025–2035. The report attributes the projected growth to rising thyroid disorders, including benign nodules and thyroid cancer. A separate 2026–2031 market report segments the market by technology, including radiofrequency and microwave ablation devices, and by applications such as benign nodules and primary or recurrent thyroid cancer. Another market overview describes a shift from traditional surgery toward digital and AI-enabled device systems.
However, it's important to note that this study had some limitations, including a relatively short follow-up period. Longer-term studies are needed to assess the durability of these treatments and to identify any potential long-term complications.
As technology evolves, MWA may become an increasingly popular choice for treating benign thyroid nodules. Its potential for reduced discomfort and efficient treatment, combined with its effectiveness in reducing nodule size, positions it as a promising alternative to traditional methods. Future research will undoubtedly refine our understanding of its benefits and optimal applications.